LIBERATE Study for Patients with Emphysema
Emphysema is a form of chronic obstructive pulmonary disease (COPD). Globally over 30 million patients have
been diagnosed with emphysema. Emphysema is a major economic problem and a burden on the global
healthcare system, due to millions of work days missed, expensive and minimally effective therapies and
frequent hospitalizations related to the disease. Most patients suffering from emphysema currently have few
options for treatment.
The Zephyr® Endobronchial Valve is an innovative minimally invasive device intended to treat patients with
emphysema. Emphysema patients suffer from hyperinflation, an increase in volume of the diseased portions of
their lungs, which then compresses the healthier areas. The Zephyr® EBV involves bronchoscopic placement of
one-way valves designed to reduce volume in the diseased portion of the lungs, with the objective of improving
the ability of the healthier portions of the lungs to function. This is expected to relieve the patient’s symptoms,
allowing them to increase their activity levels, while promoting better overall health.
United States Food and Drug Administration (U.S. FDA) has approved a request for an Investigational Device Exemption (IDE) to commence a multi-center pivotal clinical trial in 2012. The results from this trial should support
a subsequent premarket approval application (PMA) for the Zephyr® Endobronchial Valve (EBV). The Zephyr®
Endobronchial Valve (EBV) is restricted to investigational use only and not available for sale in the USA.
The Zephyr® EBV received the CE Mark approval in 2003. Since becoming commercially available in Europe
and selected countries worldwide, the company estimates that it has been used to treat approximately 6300
Endobronchial Valve Study -
• Are you age 40 to 75 years?
• Have you been a nonsmoker for at least 4 months?
• Are you able to do a 6 minute walk ( between 100 meters and 450 meters)?
If so, you may be eligible for this important study.
To find out more or to receive a patient brochure, please contact:
Theresa Boley, RN, MSN, APN/FNP, CCRP
SIU School of Medicine
701 North First Street
Springfield, IL 62702